Sanofi-logo

For US Healthcare Professional use only.
The safety and efficacy of these investigational agents have not been established.
Sjögren's Syndrome

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of Frexalimab in Adult Patients With Primary Sjögren's Syndrome (phaethuSA)

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of Frexalimab in Adult Patients With Primary Sjögren's Syndrome (phaethuSA)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of Frexalimab in Adult Patients With Primary Sjögren's Syndrome (phaethuSA) Scan and Download Back

Privacy & Data Protection        Cookies Policy
Does not include study cards for clinical programs of dupilumab.

MAT-US-2401225 v1.0 - P Exp. Date: 02/12/2026
© 2024 Sanofi. All rights reserved.